Peer-influenced content. Sources you trust. No registration required. This is HCN.

Northwestern MedicineA combination of BET inhibitor with anti-PD-1 shows promise in murine model

When tested in mice with pancreatic cancer, a BET inhibitor/anti-PD-1 combination prevented neoplastic transformation induced by the oncogene KRAS, increased survival and increased the recruitment of cytotoxic T-cells to the tumor.